GlassScriptPhysician profile
Michal Obrzut
NPI 1992983944
$2,426.41
in general payments reported to CMS, 2019-2025
23 companies · $473 in 2025
The $473 reported for 2025 was more than what 79% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $52.29 · 2021: $503 · 2022: $348 · 2023: $506 · 2024: $298 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $486.48 | 2023-2025 | Na, Agility, Spectra |
| Imperative Care, INC | $279.00 | 2022-2024 | Zoom 88-T Large Distal Platform |
| Medtronic, INC. | $272.93 | 2021-2025 | Solitaire X, Reacttm, Onyx 18 |
| Microvention, INC. | $227.97 | 2021-2022 | |
| Balt USA, LLC | $199.46 | 2021 | |
| Penumbra, INC. | $196.35 | 2019-2021 | |
| Stryker Corporation | $160.95 | 2020-2025 | Augment Injectable, Trevo |
| Terumo Medical Corporation | $125.22 | 2019-2024 | Azur Cx Detachable |
| Cardiva Medical, INC. | $91.43 | 2021-2022 | |
| Relievant Medsystems, INC. | $71.12 | 2019-2023 | Intracept |
| Chiesi USA, INC. | $45.13 | 2024 | Cleviprex |
| Bard Peripheral Vascular, INC. | $33.44 | 2022 | |
| Ucb, INC. | $26.53 | 2020 | |
| Alexion Pharmaceuticals, INC. | $25.70 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $24.75 | 2024 | Vyepti |
| Janssen Biotech, INC. | $23.57 | 2025 | |
| Tanabe Pharma America, INC. | $22.00 | 2019 | |
| Emd Serono, INC. | $21.63 | 2023 | Mavenclad |
| Boston Scientific Corporation | $21.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2024 | Austedo Xr |
| Cook Medical LLC | $14.76 | 2019 | |
| Merz Pharmaceuticals, LLC | $14.02 | 2023 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michal Obrzut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.